comparemela.com

Latest Breaking News On - மருந்து நிபுணர் குழு - Page 1 : comparemela.com

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program | Antibodies

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD) Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1 In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.